[go: up one dir, main page]

MX2022010317A - Composiciones farmaceuticas de agonistas de receptores alpha-2-adrenergicos y su uso para mejorar la vision. - Google Patents

Composiciones farmaceuticas de agonistas de receptores alpha-2-adrenergicos y su uso para mejorar la vision.

Info

Publication number
MX2022010317A
MX2022010317A MX2022010317A MX2022010317A MX2022010317A MX 2022010317 A MX2022010317 A MX 2022010317A MX 2022010317 A MX2022010317 A MX 2022010317A MX 2022010317 A MX2022010317 A MX 2022010317A MX 2022010317 A MX2022010317 A MX 2022010317A
Authority
MX
Mexico
Prior art keywords
alpha
adrenergic receptor
pharmaceutical compositions
receptor agonists
improving vision
Prior art date
Application number
MX2022010317A
Other languages
English (en)
Inventor
Ke Wu
Mohammed Dibas
Richard Graham
Massoud Fahid
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2022010317A publication Critical patent/MX2022010317A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen los métodos de uso del agonista del receptor alfa-2-adrenérgico de Fórmula I: (ver formula) Fórmula I para mejorar la visión tal como en el tratamiento de afecciones oculares tales como presbicia, mala visión nocturna, deslumbramiento visual, destellos visuales, halos visuales y algunas formas de miopía (por ejemplo, miopía nocturna).
MX2022010317A 2020-02-20 2021-02-19 Composiciones farmaceuticas de agonistas de receptores alpha-2-adrenergicos y su uso para mejorar la vision. MX2022010317A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062979214P 2020-02-20 2020-02-20
PCT/US2021/018906 WO2021168349A1 (en) 2020-02-20 2021-02-19 Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision

Publications (1)

Publication Number Publication Date
MX2022010317A true MX2022010317A (es) 2023-01-24

Family

ID=74875311

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010317A MX2022010317A (es) 2020-02-20 2021-02-19 Composiciones farmaceuticas de agonistas de receptores alpha-2-adrenergicos y su uso para mejorar la vision.

Country Status (12)

Country Link
US (2) US20210260041A1 (es)
EP (1) EP4106728A1 (es)
JP (1) JP2023514732A (es)
KR (1) KR20220157392A (es)
CN (1) CN115443125A (es)
AU (1) AU2021224232A1 (es)
BR (1) BR112022016730A2 (es)
CA (1) CA3168767A1 (es)
IL (1) IL295782A (es)
MX (1) MX2022010317A (es)
TW (1) TW202139998A (es)
WO (1) WO2021168349A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024508811A (ja) 2021-02-24 2024-02-28 オキュラ セラピューティクス，インコーポレイテッド 小管内デポーインサータ装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478858A (en) 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
AU2011207281B2 (en) 2010-01-22 2016-10-20 Allergan, Inc. Intracameral sustained release therapeutic agent implants
CA2900671A1 (en) * 2013-03-14 2014-10-02 Allergan, Inc. Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
AU2014228251B2 (en) 2013-03-15 2018-01-18 Allergan, Inc. Prostamide-containing intraocular implant
JP2016515583A (ja) 2013-03-27 2016-05-30 フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． オキュラー・インサートおよびその使用方法
RU2015146211A (ru) 2013-04-01 2017-05-19 Аллерган, Инк. Микросферная система доставки лекарственного средства для замедленного внутриглазного высвобождения
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
TW202021584A (zh) * 2018-08-21 2020-06-16 美商歐樂根公司 α2 腎上腺素受體促效劑用於改善視力之用途

Also Published As

Publication number Publication date
WO2021168349A1 (en) 2021-08-26
US20240335425A1 (en) 2024-10-10
CA3168767A1 (en) 2021-08-26
JP2023514732A (ja) 2023-04-07
TW202139998A (zh) 2021-11-01
IL295782A (en) 2022-10-01
EP4106728A1 (en) 2022-12-28
BR112022016730A2 (pt) 2022-11-08
KR20220157392A (ko) 2022-11-29
AU2021224232A1 (en) 2022-10-13
US20210260041A1 (en) 2021-08-26
CN115443125A (zh) 2022-12-06

Similar Documents

Publication Publication Date Title
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
PH12021550372A1 (en) The use of alpha-2-adrenergic receptor agonists for improving vision
US20200237916A1 (en) Ophthalmic formulation and method for ameliorating presbyopia
Nguyen et al. EyePrintPRO therapeutic scleral contact lens: indications and outcomes
PH12021550620A1 (en) Ophthalmic composition for treatment of dry eye disease
WO2019209955A3 (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
KR101789019B1 (ko) 수성 점안액
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
MY204185A (en) Composition and methods for the treatment of myopia
MX2021013447A (es) Composiciones y procedimientos para el tratamiento de enfermedades oculares.
MX2007004264A (es) Uso de inhibidores de cinasas jun n-terminales para el tratamiento de retinopat??a glaucomatosa y enfermedades oculares.
MX2021014357A (es) Metodos y formulaciones para tratar trastornos de la vision.
Bostan et al. Endophthalmitis in eyes with the Boston type I keratoprosthesis: incidence, recurrence, risk factors, and outcomes
MX2022010317A (es) Composiciones farmaceuticas de agonistas de receptores alpha-2-adrenergicos y su uso para mejorar la vision.
CY1111384T1 (el) Διαμορφωση των επιπεδων εκφρασης toy trpv
MX2023002946A (es) Composiciones y metodos para tratar presbicia, hipermetropia, astigmatismo, estereopsis disminuida, y sensibilidad al contraste disminuida.
MX2020011535A (es) Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
WO2019090010A3 (en) Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
Martidis et al. Multifocal electroretinography response after laser photocoagulation of a subretinal nematode
PH12022553289A1 (en) Ophthalmic nanoemulsion compositions
HK40107760A (en) Methods and compositions for treating mydriasis, glaucoma, and other ocular conditions
WO2024211322A3 (en) Ripasudil based ophthalmic treatments
WO2024006653A9 (en) Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms
MX2023001950A (es) Compuestos y formulaciones para el tratamiento de enfermedades oftalmicas.
Nascimento Rocha et al. Reabilitação visual após transplante penetrante de córnea com lentes de contato mini-esclerais